Eli Lilly says about 100 jobs will be lost in its dry products operations as it rejiggers tablet and capsule production over the next several years, but that employees will have the chance to move to other positions, like in its growing insulin operations.
Contract services company Aptuit will invest $1 million in its facility in Glasgow, Scotland, to expand its capacity to manufacture sterile cytotoxic liquid and lyophilized drug products.
Johnson & Johnson has managed a turnaround in its McNeil Consumer Health division by producing products like Tylenol and Motrin at facilities other than its still-closed Fort Washington, PA, plant and getting them back on retailer's shelves.
The sterile injectables business holds promise for drugmakers with the manufacturing capabilities to produce the difficult-to-make drugs. Deals announced Wednesday by Pfizer and Sun Pharma were proof positive of how companies think they can cash in on the generics piece of this sterile injectables market.
Purdue Pharma will build a new $59 million plant in Durham, NC, and has awarded a contract to KBR Building Group to erect the 188,000-square-foot facility.
Glenmark has more than a dozen manufacturing plants around the world, recently opening a mAb manufacturing facility in Switzerland to feed its pipeline of monoclonal antibodies and biosimilars. But the Indian generics maker does not have a plant in North America and figures it is time.
Pfizer has a reputation for being a company that will cut jobs deeply once a merger is done, a rap that raised a lot of fears during its run at AstraZeneca. But the U.S. drugmaker can now point to about 100 jobs in Ireland that it is sparing as business has improved.
The deal gives Xellia capacity in North America for the first time, providing the company with a platform from which to realize the mid-term growth opportunities envisaged by Novo A/S when it bought the company.
The $218 million takeover gives Hospira an API plant and 665 staff in Aurangabad, India, furthering its ambition to become less reliant on third-party ingredient suppliers.
Having spent the past few months trying to bring standards at its Quebec City vaccine plant in line with FDA expectations, GlaxoSmithKline must now work to satisfy another regulator: Health Canada. The Canadian regulator sent GSK an inspection report late last week and gave the Big Pharma 30 days to come up with a plan to fix the problems faced by the facility.